> Epigenetics Shapes Fate of Brain vs. Brawn Castes in Carpenter Ants
> Molecular Master Switch for Pancreatic Cancer Identified, Potential Predictor of Treatment Outcome
> Eat to Dream: Penn Study Shows Dietary Nutrients Associated with Certain Sleep Patterns
  All News Releases
    Media Resources
NOVEMBER 4 , 2008
  PENN Medicine Psychiatrists Find Combination Medication, Extended Treatment Reduce Teen Opiate Addiction Relapses

For the growing number of teens addicted to opiates (i.e. heroin or prescription pain-relief drugs), short-term detoxification and/or psychosocial treatment programs are commonly recommended, despite high relapse rates and limited success. Researchers have found a more effective treatment method that targets the physiological aspects of opioid addiction, which may reduce the toll drug abuse takes on individuals, families, and communities.

A study appearing in the November 5 issue of JAMA shows that extended-treatment with buprenorphine-naloxone (suboxone) for opioid-addicted youth resulted in much less drug use, injecting and treatment dropout than short-term detoxification alone. The NIH-funded study, led by George Woody, MD, Professor of Psychiatry at the University of Pennsylvania School of Medicine, was conducted at 6 sites in the National Institute on Drug Abuse (NIDA) Clinical Trials Network.

"Effective medication should not be excluded or stopped simply because the patient is young and has been addicted to opioids for a short time - the high level of opioid use after the last dose of medication seen in both arms of this study resembled detoxification in opioid-dependents adults having much longer periods of addiction," said Dr. Woody. "Although we did not determine how long the medication should be continued, the study showed that it is a very useful addition to counseling and other psychosocial treatment services for outpatient treatment of opioid addicted youth. Clinicians should be in no hurry to stop this combination medication treatment."

Please read the JAMA press release or full study for more information.


PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s top ten “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.


Media Contacts
Kim Guenther
(215) 662-6183

Related Links
Perelman School of Medicine
University of Pennsylvania Health System

Recommend Story

About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2016, The Trustees of the University of Pennsylvania